| Amgen Contract Update |
 |
| Oncology Associates' agreement with Amgen for purchases of Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim) and Neupogen® (filgrastim) has recently been updated. |
 |
| Click here to learn more (pdf) |
 |
 |
 |
| ELOXATIN 200 mg on Back-Order |
 |
| Sanofi Aventis has announced that effective immediately, ELOXATIN® (oxaliplatin injection), 200mg will be put on back-order status. |
 |
| Click here to learn more (pdf) |
 |
 |
 |
New Agreement with Merck: Emend for Injection |
 |
| Oncology Associates is pleased to announce a new agreement with Merck for Emend for Injection (fosaprepitant dimeglumine). The agreement will run from July 1, 2008 through June 30, 2010. |
 |
| Click here to learn more (pdf) |
 |
 |
 |
| Eloxatin Now Available in 200 MG Vial |
 |
| More convenience, efficiency and safety with single vials of Eloxatin. |
 |
| Click here to learn more (pdf) |